Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Mylan N.V.
Type
Naamloze vennootschap
Traded as NASDAQ: MYL
NASDAQ-100 Component
NASDAQ Biotechnology Index Component
S&P 500 Component
Industry Pharmaceuticals
Founded White Sulphur Springs, West Virginia, United States (1961)
Founder Milan Puskar
Don Panoz
Headquarters Amsterdam, The Netherlands
Key people
Heather Bresch (CEO)
Products Generic and specialty pharmaceuticals and active pharmaceutical ingredients
Revenue Increase US$ 7.72 billion (2014)
Operating income
Increase US$ 1.01 billion (2011)
Net income
Increase US$ 640.9 million (2012)
Total assets Increase US$ 11.598 billion (2011)
Total equity Decrease US$ 3.504 billion (2011)
Number of employees
approximately 30,000 (2015)
Website www.mylan.com

Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters in Hatfield, Hertfordshire in the United Kingdom. In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients (APIs) for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, Mylan has grown from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world. Mylan now has approximately 30,000 employees, more than 1,000 separate products, and serves customers in more than 150 countries and territories. Mylan has a global manufacturing output of more than 45 billion doses.

Famy Care
(Acq 2014)

Abbott Laboratories
(Acq 2014, Generics division)

Merck KGaA
(Acq 2007, Generics division, renamed Mylan Laboratories Inc)

UDL Laboratories
(Acq 1996)

Bertek Inc
(Acq 1993, renamed Mylan Technologies Inc)

Milan Pharmaceuticals
(Founded 1961)

Investment goal date:
Dividends reinvested
Mylan N.V. MYL report Q2 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q4 2017
2018-02-23
--
--
Q3 2017
2017-11-06
--
--
Q2 2017
2017-08-09
1.1000
0.5500
Q1 2017
2017-05-10
0.9300
0.1200
Q4 2016
2017-03-01
1.5700
0.7800
Q3 2016
2016-11-09
1.3800
-0.2300
Q2 2016
2016-08-09
1.1600
0.3300
Q1 2016
2016-05-03
0.7600
0.0300
Q4 2015
2016-02-10
1.2200
0.3800
Q3 2015
2015-10-30
1.4300
0.8300
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BlackRock Fund Advisors
14351821
BlackRock Inc.
38822643
BlackRock Institutional Trust Company, N.A.
12222840
FRANKLIN RESOURCES INC
10009206
GOLDMAN SACHS GROUP INC
7449122
GREENLIGHT CAPITAL INC
8692307
Invesco Ltd.
13111379
Laurion Capital Management LP
5630656
PAULSON & CO INC
17474387
PRICE T ROWE ASSOCIATES INC /MD/
6890175
PZENA INVESTMENT MANAGEMENT LLC
7262316
STATE STREET CORP
20176564
UBS Group AG
7512982
Vanguard Group, Inc
29348816
WELLINGTON MANAGEMENT CO LLP
46373108
Major Shareholders
Name Relationship
Total Shares
Holding stocks
TODD C B
0.0100% (23389)
MYL /
RIZZO DANIEL C JR
0.0200% (82758)
MYL /
% ()